梯瓦制药Teva Pharmaceutical Industries（TEVA）2025年10-K年度报告「NYSE」（英文版）（227页）.pdf

1、?UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549?FORM 10-K?(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2025?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 19

2、34For the transition period from to Commission file number 001-16174TEVA PHARMACEUTICAL INDUSTRIES LIMITED(Exact name of registrant as specified in its charter)?Israel Not Applicable(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)?400 Interpace Parkway,

3、#3Parsippany NJ,07054 USA+1-973-658-0301 124 Dvora HaNevia St.,Tel Aviv,ISRAEL,6944020+972(3)914-8213(Address of principal executive offices,zip code and telephone number,including area code)?Securities registered pursuant to Section 12(b)of the Act:?Title of each class Trading Symbol(s)Name of each

4、 exchange on which registeredAmerican Depositary Shares,eachrepresenting one Ordinary Share TEVA New York Stock ExchangeSecurities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.

5、Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the

6、preceding 12months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be su